Nama's AI scorecard currently rates Relay Therapeutics Sell (3.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does RLAY report earnings?

Relay Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.35.

What is the RLAY price target?

The median analyst price target from 12 analysts is $27.50, with a range of $20.00 – $32.00.

Is RLAY Shariah compliant?

Nama's AAOIFI-style screen reads Relay Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Relay Therapeutics (RLAY)

Healthcare · Biotechnology · NASDAQ

Relay Therapeutics (RLAY) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $4.11B and a free-cash-flow yield of -7.4%. Over the most recent reported fiscal year, revenue grew 53.4%. Nama's AI scorecard rates it Sell, 3.1 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +174.9% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-49.2%

How far the last close sits under the highest price of the past five years.

Market cap	$4.11B
Trailing P/E	—
Price / book	4.6
Price / sales	372.0
FCF yield	-7.4%
Dividend yield	—
Gross margin	0.0%
Operating margin	-25949.7%
Net margin	0.0%
Revenue growth (YoY)	+53.4%
Revenue growth (3-yr annual)	+123.2%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.7
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

RLAY earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.35). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.37	-$0.40	+7.5%	$0
Q2 2026	Aug 6, 2026	-$0.41	-$0.39	-5.1%	$350,000
Q1 2026	May 5, 2026	-$0.41	-$0.36	-13.9%	$3.00M
Q4 2025	Feb 26, 2026	-$0.31	-$0.40	+22.5%	$7.00M

RLAY analyst price target

Median target $27.50 from 12 analysts, ranging $20.00 – $32.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live RLAY data on Nama Insights →

Recent Congressional trades

Relay Therapeutics trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Daniel Goldman	House	Sell	$1,001 - $15,000	Aug 13, 2023

RLAY FAQ

Is RLAY a buy?: Nama's AI scorecard currently rates Relay Therapeutics Sell (3.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does RLAY report earnings?: Relay Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.35.
What is the RLAY price target?: The median analyst price target from 12 analysts is $27.50, with a range of $20.00 – $32.00.
Is RLAY Shariah compliant?: Nama's AAOIFI-style screen reads Relay Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.